54488-64-1

Basic information

• Product Name: Hydroxylamine, O-cyclohexyl-, hydrochloride
• CAS NO: 54488-64-1
• Molecular Formula: C6H13NO.ClH
• Molecular Weight: 151.636
• Mol File: 54488-64-1.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Hydroxylamine, O-cyclohexyl-, hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Hydroxylamine, O-cyclohexyl-, hydrochloride(54488-64-1)
• EPA Substance Registry System: Hydroxylamine, O-cyclohexyl-, hydrochloride(54488-64-1)

Safety Data

• Hazardous Substances Data: 54488-64-1(Hazardous Substances Data)

Upstream product

• 4759-21-1 O-cyclohexyl-hydroxylamine 
• 1226995-33-0 C₁₀H₁₉NO₂ 
• 169956-61-0 2-(cyclohexyloxy)-1H-isoindole-1,3(2H)-dione 
• 76029-42-0 2-(cyclohex-2-en-1-yloxy)isoindoline-1,3-dione 
• 1521-51-3 rac-3-bromocyclohexene 

Downstream Products

• 1033779-97-3 (E)-2-[2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclohexyloxyimino-acetylamino]-thiazole-5-carboxylic acid amide 
• 1033779-96-2 (E)-N-benzothiazol-2-yl-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclohexyloxyimino-acetamide 
• 1033779-95-1 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclohexyloxyimino-N-(3-methyl-[1,2,4]thiadiazol-5-yl)-acetamide 
• 1033779-94-0 (E)-2-(3-chloro-4-methanesulfonyl-phenyl)-2-cyclohexyloxyimino-N-(1-methyl-1H-pyrazol-3-yl)-acetamide 
• 1033780-23-2 (E)-(3-chloro-4-methanesulfonyl-phenyl)-cyclohexyloxyimino-acetic acid 
• 1433194-97-8 ethyl 2-ethoxy-3-{4-[2-(5-{1-[E-cyclohexyloxyimino]ethyl}indol-1-yl)ethoxy]phenyl}propionate 
• 1391835-97-4 C₂₂H₂₆FN₅O₄ 
• 1391836-63-7 C₂₀H₃₅N₃O₅ 
• 1391836-53-5 C₁₅H₂₇N₃O₃ 
• 1391836-43-3 C₂₃H₂₉N₃O₅ 
• 1391836-33-1 C₁₅H₂₆N₂O₄ 
• 1391836-23-9 C₃₁H₄₄N₂O₄Si 
• 1318796-35-8 (E)-dimethyl 2-(cyclohexyloxyimino)-3-diazosuccinate 
• 1318796-77-8 dimethyl 2-(cyclohexyloxyimino)succinate 

Relevant articles and documents

Ammonia oxide makes up some 20% of an aqueous solution of hydroxylamine

Three independent indirect estimates based on structure-reactivity correlations indicate that ca. 20% of hydroxylamine exists in aqueous solution as ammonia oxide, NH3+-O-.

NOVEL VASCULAR LEAKAGEAGE INHIBITOR

The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

Design, Synthesis, and invitro Antibacterial Activity of Fluoroquinolone Derivatives Containing a Chiral 3-(Alkoxyimino)-2-(aminomethyl)azetidine Moiety

A series of novel (R)/(S)-7-(3-alkoxyimino-2-aminomethyl-1-azetidinyl)fluoroquinolone derivatives were synthesized and evaluated for their invitro antibacterial activity against representative strains. Our results reveal that 12 of the target compounds generally show better activity (MIC: -1) against the tested Gram-positive strains including MRSA and MRSE than levofloxacin (LVFX, MIC: 0.125-8μgmL-1). Their activity is similar to that of gemifloxacin (GMFX, MIC: -1). However, they are generally less active than the two reference drugs against Gram-negative strains. Moreover, against clinical strains of S.aureus including MRSA and S.epidermidis including MRSE, the MIC50 values (0.06-16μgmL-1) and MIC90 values (0.5-32μgmL-1) of compounds 16w, y, and z are 2-8- and 2-16-fold less than LVFX, respectively, and 16w (MIC90 range: 0.5-4μgmL-1) was also found to be more active than GMFX (MIC90 range: 1-8μgmL-1).